Stem Cell Therapeutic and Research Reauthorization Act of 2026
Bill Summary
Reauthorizes funding for stem cell research and therapy programs. Extends existing programs to continue supporting medical research and treatment development using stem cells.
Sponsored By
Bill Journey
- Mar 17, 2026
- Jun 22, 2026You Are Here
The full chamber debates the bill, may amend it, and votes on whether to pass it.
- TBD
If passed by the first chamber, the other chamber considers, may amend, and votes on the bill.
- TBD
If passed by both chambers, the bill goes to the President to sign into law or veto.
Why It Matters
This bill affects medical researchers, patients with diseases or injuries that could be treated with stem cell therapies, and families relying on these treatments, by providing continued funding for research and development of new therapies. It also impacts healthcare providers and organizations involved in stem cell research and treatment.
Impact Areas
Support & Opposition
- Democratic2
- Republican2
Documents
1
Full text opens on congress.gov, the official source.
Cosponsors (3)
Bill Details
- Health
Summary and impact analysis written by Judy (KnowGov's enrichment AI). Bill metadata, status, sponsor, and any floor votes from Prism. Sections marked “Sample” are placeholders not yet connected to live data.



